Company intelligence / Profile preview
Regentis Biomaterials
Herzliya, Tel Aviv District, Israelregentis.co.il ↗
- Ownership
- Private
- Employees
- ~3
- Development stage
- Phase 3
01
Overview
Regentis Biomaterials has developed GelrinC, a cell-free hydrogel implant for articular cartilage repair. The product has demonstrated promising results in European clinical trials—showing improvement in pain and function—and received CE mark approval. In the US, it remains investigational and under evaluation through expanded SAGE clinical trials at multiple sites. The technology leverages a unique blend of polyethylene glycol diacrylate and denatured fibrinogen to create an off-the-shelf scaffold that supports endogenous stem cell-driven regeneration.
- Therapeutic areas
- Rheumatology
- Modalities
- Device (hydrogel implant)Hydrogel-based drug delivery therapyBiologic (denatured fibrinogen component)Polymer-drug conjugate therapy (polyethylene glycol diacrylate/fibrinogen matrix)
- Industry
- Implantable Medical Devices
02
Drug pipeline
1 asset03
Partnerships
No major pharma partnerships disclosed; seeking strategic partners for commercialization especially in Europe.
Beyond the preview
Go deeper on Regentis Biomaterials.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Regentis Biomaterials.